EGFR and non-small cell lung carcinoma: This suggests that BRAF-mutant NSCLC, particularly those with Class I and higher PD-L1, may be more responsive to ICIs compared to other oncogene-driven NSCLCs (i.e., EGFR or ALK) (18, 45–49).